Tamir Biotechnology
Monmouth Junction
About Tamir Biotechnology
Tamir Biotechnology, Inc., a biopharmaceutical company, primarily engages in the discovery and development of a class of therapeutic drugs for the treatment of cancer and other pathological conditions. Its proprietary drug discovery and development program consists of therapeutics developed from amphibian ribonucleases. The company’s lead drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. Tamir Biotechnology also focuses on new drug application for unresectable malignant mesothelioma. In addition, it completed a Phase I clinical trial for the treatment of non-small cell lung cancer. The company was formerly known as Alfacell C...
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $7.3M
- Funding stage: M&A
- Last round: Series Unknown (May 2016)
- Website: tamirbio.com
- Phone: 17326524575
Industries & Categories
Biotechnology, Hospital, Therapeutics
Canonical: https://fsome.com/organization/tamir-biotechnology-125967 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.